Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Epinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.72 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.72 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.72 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.72 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.72 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.72 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 0.72 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.72 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 11/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.72 |
| ▸ | DRD2 | P14416 | 5/20 | 0.72 |
| ▸ | RECQL | P46063 | 5/20 | 0.72 |
| ▸ | TSHR | P16473 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL11236186 | 1.00 | MAPT (0.72) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Epinephrine SCHEMBL11236183 | 1.00 | MAPT (0.72) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Racepinephrine SCHEMBL27540379 | 1.00 | MAPT (0.72) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Epinephrine SCHEMBL8465140 | 0.96 | TDP1 (0.67) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Isoproterenol SCHEMBL10786267 | 0.86 | MAPT (0.74) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Epinephrine SCHEMBL2691388 | 0.85 | TDP1 (0.93) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| L-Adrenaline SCHEMBL11647 | 0.85 | KDM4E (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Racepinephrine SCHEMBL3815 | 0.85 | KDM4E (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Racepinephrine SCHEMBL11631789 | 0.85 | KDM4E (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Racepinephrine SCHEMBL20493843 | 0.85 | KDM4E (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173374-A1 | LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS | OHIO STATE INNOVATION FOUNDATION | 2024-05-30 | — | — | US | claimed |
| EP-1315835-A2 | DIRECTED DIFFERENTIATION OF EMBRYONIC CELLS | Yissum Research Development Company of the Hebrew University of Jerusalem (IL) | 2003-06-04 | — | — | EP | claimed |
| US-20020146678-A1 | Directed differentiation of embryonic cells | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2002-10-10 | — | — | US | claimed |
| WO-2002010347-A2 | DIRECTED DIFFERENTIATION OF EMBRYONIC CELLS | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2002-02-07 | — | — | WO | claimed |
| CN-117024516-A | Polypeptide mimic enzyme, preparation method thereof and application thereof in preparation of nerve substance detection reagent | 天津大学 | 2023-11-10 | — | — | CN | disclosed |
| US-10744140-B2 | Synergistic nutraceutical beverage formulations providing enhanced thermogenesis, mental clarity, and stamina while minimizing adrenaline and dopamine concentration perturbations associated with withdrawal | POWER SUPPLEMENTS, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180055849-A1 | NUTRACEUTICAL CAPSULE AND TABLET FORMULATIONS PROVIDING ENHANCED MENTAL CLARITY, CONCENTRATION AND STAMINA WHILE MINIMIZING ADRENALINE AND DOPAMINE CONCENTRATION PERTURBATIONS ASSOCIATED WITH WITHDRAWAL | POWER SUPPLEMENTS, LLC | 2018-03-01 | — | — | US | disclosed |
| US-20180055850-A1 | SYNERGISTIC NUTRACEUTICAL BEVERAGE FORMULATIONS PROVIDING ENHANCED THERMOGENESIS, MENTAL CLARITY, AND STAMINA WHILE MINIMIZING ADRENALINE AND DOPAMINE CONCENTRATION PERTURBATIONS ASSOCIATED WITH WITHDRAWAL | POWER SUPPLEMENTS, LLC | 2018-03-01 | — | — | US | disclosed |
| EP-3102206-A1 | COMBINATIONS OF IKK /TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS | The Regents Of The University Of Michigan (US) | 2016-12-14 | — | — | EP | disclosed |
| CN-106132413-A | IKK ε/TBK1 inhibitor and Beta-3 adrenergic agonist or the combination of sympathetic nervous system activator | 密歇根大学董事会 | 2016-11-16 | — | — | CN | disclosed |
| US-20150224089-A1 | COMBINATIONS OF IKKi/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | disclosed |
| WO-2015119624-A1 | COMBINATIONS OF IKKε/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-08-13 | — | — | WO | disclosed |
| US-5411883-A | Proliferated neuron progenitor cell product and process | SOMATIX THERAPY CORPORATION (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0527954-A4 | MOLECULAR RECOGNITION UNITS | — | 1993-09-01 | — | — | EP | disclosed |
| US-5196510-A | Polypeptides | CYTOGEN CORPORATION (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0527954-A1 | MOLECULAR RECOGNITION UNITS | CYTOGEN CORPORATION (US) | 1993-02-24 | — | — | EP | disclosed |
| WO-1991017173-A1 | MOLECULAR RECOGNITION UNITS | CYTOGEN CORPORATION (US) | 1991-11-14 | — | — | WO | disclosed |
| WO-1990007713-A1 | MOLECULAR RECOGNITION UNITS | CYTOGEN CORPORATION (US) | 1990-07-12 | — | — | WO | disclosed |
| EP-0342211-A1 | TREATMENT OF ARTERIOSCLEROSIS BY ADMINISTRATION OF L-TRYPTOPHAN OR L-5-HYDROXYTRYPTOPHAN. | UNIV FLORIDA (US) | 1989-11-23 | — | — | EP | disclosed |
| WO-1989002737-A1 | TREATMENT OF HYPERTENSION BY CHRONIC ADMINISTRATION OF L-TRYPTOPHAN OR L-5-HYDROXYTRYPTOPHAN | UNIVERSITY OF FLORIDA (US) | 1989-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173374-A1 | LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS | LIPA, CHMP4B, VMA21 | ADRB2 3920/4885ADRB1 4013/4885ADRA2A 2249/4885 |
| US-20180055849-A1 | NUTRACEUTICAL CAPSULE AND TABLET FORMULATIONS PROVIDING ENHANCED MENTAL CLARITY, CONCENTRATION AND STAMINA WHILE MINIMIZING ADRENALINE AND DOPAMINE CONCENTRATION PERTURBATIONS ASSOCIATED WITH WITHDRAWAL | SNCA, HIRA, HTR5A | ADRB2 106/4885ADRB1 138/4885ADRA2A 27/4885 |
| US-20150224089-A1 | COMBINATIONS OF IKKi/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS | TBK1, NFKBIA, ADRB1 | ADRB2 13/4885ADRB1 3/4885ADRA2A 27/4885 |
| US-20180055850-A1 | SYNERGISTIC NUTRACEUTICAL BEVERAGE FORMULATIONS PROVIDING ENHANCED THERMOGENESIS, MENTAL CLARITY, AND STAMINA WHILE MINIMIZING ADRENALINE AND DOPAMINE CONCENTRATION PERTURBATIONS ASSOCIATED WITH WITHDRAWAL | COMT, PYGB, MAOB | ADRB2 76/4885ADRB1 125/4885ADRA2A 56/4885 |
| US-10744140-B2 | Synergistic nutraceutical beverage formulations providing enhanced thermogenesis, mental clarity, and stamina while minimizing adrenaline and dopamine concentration perturbations associated with withdrawal | COMT, PYGB, MAOB | ADRB2 76/4885ADRB1 125/4885ADRA2A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.